Together, we reveal an unexpected role for the tyrosine kinase SYK in maintaining STAT3 phosphorylation in basal-like breast cancer and provide a rationale for clinically testing SYK small-molecule inhibitors in this subclass of tumors. This evidence concerns the gene SYK and breast carcinoma.